A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects
Clinical trial NCT06310746 · COMPLETED
Trial details
- NCT number
- NCT06310746
- Sponsor
- Shanghai Henlius Biotech
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-23
- Primary completion
- 2025-07-30
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.